-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article Source: Immediate Medicine News
On July 21st, Merck (MSD) and Bayer (Bayer) jointly announced that the European Commission (EC) has approved the listing of its soluble guanylate cyclase (sGC) stimulant Verquvo (vericiguat) for the treatment of adults with reduced ejection fraction Patients with symptomatic chronic heart failure who have stabilized after a recent decompensated event that required intravenous (IV) therapy
Reduced ejection fraction (HFrEF) heart failure, formerly known as systolic heart failure, is characterized by impaired ability of the heart to eject blood adequately during its contraction phase
Heart failure is related to nitric oxide (NO) synthesis disorder and decreased sGC activity
Verquvo was jointly developed by Merck and Bayer.
Note: The original text has been deleted
Reference materials:
[1] VERQUVO® (vericiguat) Approved in the European Union.